Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
Executive Summary
Risk Evaluation and Mitigation Strategy for Kymriah requires the acute lymphoblastic leukemia treatment be administered by certified centers, while a postmarketing study will assess safety over 15 years. FDA's early approval reflects efforts by the biologics center and new cross-cutting Oncology Center for Excellence to implement a more collaborative review model.
You may also be interested in...
CAR-T Cell Product Development Guidance Covers Previous Recipients, ‘Bridging Therapy’
Testing of autologous therapy in clinical trial patients who previously received CAR-T cells requires special consideration in initial material testing and study design, US FDA says in a draft guidance that also addresses potential need for bridging therapy in the event of a manufacturing delay or failure.
CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah
'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.
Immuno-Oncology: Execs Talk About Tumor Response, Biomarkers, Lessons Learned
Leaders from Novartis and other companies developing cellular gene therapies share insights they've gleaned on manufacturing, clinical trials, and value-based pricing.